(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Songbirds swap colorful plumage genes across species lines among their evolutionary neighbors - 2Horses really can smell our fear, new study finds
- 33 astronauts settle into their new life in orbit | On the International Space Station this week Dec. 1-5, 2025
- 4Russia earning billions from Hormuz blockade, German trade body says
- 5Dozens of hidden star streams found in the outskirts of our Milky Way galaxy
- Earthquake in Indonesia kills at least 1 person and sets off small tsunami
- 10 Demonstrated Tips to Dominate Video Altering on Your Cell phone in 2023
- New nesting beach for birds at RSPB reserve
- Activists guilty over Palestine protest breach
- Fire Allegedly Triggered by Wedding Cake Sparkler Causes Venue to Go Up in Flames, Leaving Groom with Second-Degree Burns
- Going with Children: Tips for Tranquil Family Get-aways
- NMG signs new graphite supply deal with Canadian Government
- Instructions to Keep an Inspirational perspective After Cellular breakdown in the lungs Treatment
- The Best Traditional Music Arrangers in History
